Full-Time

Head of IT Security

Posted on 11/7/2025

PTC Therapeutics

PTC Therapeutics

1,001-5,000 employees

Biopharmaceuticals for rare genetic disorders

Compensation Overview

$229.2k - $310k/yr

+ Bonus + Equity

Middlesex, NJ, USA

In Person

Category
IT & Security (1)
Required Skills
Microsoft Azure
Management
AWS
Risk Management
Requirements
  • A bachelor’s degree in computer science, Information Systems or other related field and a minimum of 15+ years of progressively responsible leadership experience, preferably in a pharmaceutical, biotechnology or other regulated environment OR equivalent experience and/or education.
  • Over 15+ years of experience in hands-on roles focused on Privacy, Data Protection, or Data Security or Security Operations.
  • Strong understanding of global data privacy regulations and guidelines, such as GDPR, CCPA, and PIPEDA.
  • Proficiency with Data Loss Prevention tools, including network, endpoint, and cloud-based DLP solutions.
  • Relevant experience in designing, implementing, and supporting large-scale solutions.
  • Skilled in drafting standards, reference architecture, policies, procedures, and implementation guidelines.
  • Exceptional writing skills tailored for technical, management, and executive audiences.
  • Effective communication skills, including oral presentations and the ability to present to executive leadership.
  • Proven experience in managing multiple concurrent issues under high-pressure situations.
  • High proficiency in Cryptographic Services.
  • Experience with cloud environments like Azure and Amazon Web Services.
  • Proficiency in Microsoft Office.
  • Excellent verbal and written communication and presentation skills.
  • Ability to work independently and collaboratively in a fast-paced, matrixed team environment with internal and external members.
  • Analytical thinker with strong problem-solving skills, adaptable to changing priorities and deadlines.
  • Excellent planning, organizational, and time management skills, including the ability to support and prioritize multiple projects.
Responsibilities
  • Stays updated on security trends and the evolving threat landscape, actively engaging with vendors to understand security roadmaps, technology directions, and investments aimed at enhancing security capabilities and delivering cost-effective solutions.
  • Creates high-quality documentation for strategic security vision, encompassing blueprints, standards, and frameworks that align with the overall business strategy.
  • Leads the development and updating of standards and reference materials, ensuring compliance with regulations mandated by various authorities.
  • Establishes, implements, and oversees a strategic, comprehensive enterprise information security and IT risk management program to ensure the integrity, confidentiality, and availability of information owned, controlled, or processed by the organization.
  • Collaborates across departments to ensure effective security processes and procedures.
  • Focus on strategy, planning, and operational excellence through continuous improvement and automation.
  • Manages the administration of all information security technology platforms, ensuring optimal configuration and maintenance for maximum uptime and protection of the organization's information systems.
  • Plays a key role in selecting new information security tools and technologies.
  • Conducts regular technical risk assessments and audits of systems and processes.
  • Manages the IT security organization, including hiring, training, staff development, and other managerial responsibilities.
  • Coordinates with internal teams as needed, overseeing annual audits and reporting requirements.
  • Develops, maintains, and disseminates up-to-date security policies, standards, and guidelines, overseeing training and distribution of security practices.
  • Provides tactical leadership for all information security platforms.
  • Acts as the escalation point for internal and external breaches, including those involving third parties.
  • Leads the response and containment of information security incidents.
  • Takes charge in developing and managing information security programs, including awareness initiatives, vulnerability management, vendor risk management, and risk management.
  • Responsible for initial and periodic information security risk assessment, analysis, mitigation, and remediation.
  • Assists in developing and transferring knowledge to IT team members and other enterprise groups.
  • Performs additional tasks and assignments as specified by management.
Desired Qualifications
  • CISSP, CISM, CISA, GIAC, GPEN, or PMP certification is preferred.

PTC Therapeutics is a global biopharmaceutical company that discovers, develops, and markets medicines for rare genetic diseases. It uses RNA biology and post-transcriptional control to create therapies, including small-molecule drugs and gene therapies. Its products include Translarna for nmDMD, Evrysdi for SMA, Emflaza, Upstaza for AADC deficiency, and Kebilidi for CNS indications, all supported by an integrated model from research to commercialization and operations in more than 50 countries with a European base in Dublin. The company aims to provide safe, effective treatments to patients with few or no options by building a strong pipeline and broad global access.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

South Plainfield, New Jersey

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Sephience hits $125M Q1 2026 revenue with 1,244 patients worldwide.
  • Votoplam PIVOT-HD data slows Huntington's progression 52%, unlocks $50M Novartis milestone.
  • Raised 2026 product revenue guidance to $750-850M on Sephience expansion.

What critics are saying

  • FDA CRL rejects vatiquinone NDA August 2025, demands new trial before resubmission.
  • Emflaza generics erode DMD franchise revenue immediately post-patent expiry.
  • Translarna risks EU approval loss from confirmatory trial failure within 6-12 months.

What makes PTC Therapeutics unique

  • Vatiquinone selectively inhibits 15-LO to reduce oxidative stress in Friedreich's ataxia.
  • Sephience employs dual mechanism driving 36% Q1 2026 revenue growth.
  • PTC518 leverages RNA biology for oral Huntington's mutant protein reduction.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Flexible Work Hours

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
PR Newswire
Mar 25th, 2026
PTC Therapeutics appoints biotech banking pioneer Jessica Chutter to board

PTC Therapeutics has appointed Jessica Chutter to its Board of Directors. Chutter recently retired as Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley after over 40 years with the firm. Chutter is considered a pioneer in biotechnology investment banking, having helped build Morgan Stanley's biotechnology banking practice. During her tenure, she was involved in approximately $80 billion of capital raising and $85 billion of strategic transactions. She holds a BA from McGill University and an MBA from Harvard University. PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing and commercialising medicines for rare disorders in children and adults. The company aims to leverage Chutter's expertise as it continues its growth trajectory.

PTC Therapeutics
Mar 4th, 2026
PTC earns Gallup's Exceptional Workplace Award for fifth year.

PTC earns Gallup's Exceptional Workplace Award for fifth year. PTC has been named a 2026 Gallup Exceptional Workplace Award winner. This is the company's fifth time earning this important recognition, and it reflects the culture PTC Therapeutics, Inc. has cultivated by enabling its people do their best work by leading with their Strengths. At PTC, PTC Therapeutics, Inc. use Gallup's CliftonStrengths to build a shared Strengths language that supports individual growth and strengthens collaboration across teams. PTC Therapeutics, Inc. encourage every employee to deepen their Strengths through coaching and ongoing conversations that turn individual strengths into meaningful impact. With this 2026 Exceptional Workplace Award, Gallup has recognized PTC for: * Strong leadership commitment to sustaining a Strengths-based culture * Deep integration of Strengths into its business and ways of working * Global One PTC approach that strengthens collaboration across teams and regions "Being recognized by Gallup for the fifth time is a powerful reflection of the consistency and care our people bring to PTC every day," said Hege Sollie-Zetlmayer, Chief Human Resources Officer. "When we lead with Strengths, we build teams that collaborate better and deliver stronger results, and that enables us to stay focused on our purpose and the patients and families we serve." PTC Therapeutics, Inc. is proud of this achievement, as it is a testament to its collective dedication to nurturing a work environment that enables employees to reach their full potential. PTC Therapeutics, Inc. celebrate this recognition with its One PTC team and continue to build upon its culture of empowerment and success. About the Gallup's 2026 Exceptional Workplace Award Gallup Exceptional Workplace Award winners change the way people work around the world. They achieve this by focusing on the engagement and Strengths of their people and investing in their development. Gallup created the Gallup Exceptional Workplace Awards to honor and recognize this commitment to developing human potential. Winners have workplace cultures that put the strengths of leaders, managers, and employees at the core of how they work every day. These achieve more by helping employees focus on what they do best, maximizing potential within teams, and integrating Strength-accelerated development into their mission, vision, and values. Learn more here.

Yahoo Finance
Mar 3rd, 2026
Palo Alto Investors adds $3M stake in PTC Therapeutics with 41,000 new shares

Palo Alto Investors LP purchased 41,303 shares of PTC Therapeutics in the fourth quarter of 2025, worth approximately $3 million, according to a 17 February 2026 SEC filing. The investment manager's stake in the biotech company increased to $68.66 million, up $15.72 million from the previous period. PTC Therapeutics now represents 9.6% of Palo Alto Investors' reportable assets under management. The biotech company, which specialises in treatments for rare diseases including Duchenne muscular dystrophy and spinal muscular atrophy, has seen its shares rise 39.9% over the past year to $69.17. The deal marks the fund's third major position in the biotechnology sector, behind Insmed and Amicus Therapeutics. PTC Therapeutics reported revenues of $806.78 million but remains unprofitable.

PharmaVoice
Oct 14th, 2025
What a gene therapy win means for the Huntington's disease pipeline

What a gene therapy win means for the Huntington's disease pipeline. Recent results for a Huntington's gene therapy confer a hopeful sign for R&D in the space. The Huntington's disease community celebrated a much-needed win last month when results for a gene therapy demonstrated slowed disease progression for the vexing neurological disorder. The phase 1/2 readout for uniQure's AMT-130 not only buoyed hopes for a disease-modifying option, but gave the larger field a boost by renewing confidence for a central hypothesis in Huntington's research: that lowering levels of a toxic protein can help keep symptoms at bay. "Beyond UniQure, the pipeline includes highly promising approaches that will ideally move the goal from merely managing symptoms to effectively controlling the disease," Amy Gray, president and CEO of the Huntington's Disease Society of America, said in an email. Huntington's research has been beset by a series of demoralizing drug failures. For a time, it appeared that uniQure's one-and-done gene therapy might join the discard pile. In 2022, the phase 1/2 trial ground to a halt when three patients in the high-dose treatment arm experienced serious neurological side effects, believed to be related to the surgical procedure that delivers the therapy deep into the most affected part of the brain. However, the three affected participants recovered and the trial continued. The uniQure gene therapy uses a viral vector to deliver a gene encoding an miRNA designed to bind to and reduce levels of the huntingtin protein, which is crucial for proper nerve function. Huntington's is linked to a mutation in the huntingtin gene, and people with the condition produce a mutated form of the protein, which creates damaging clumps in the brain that are thought to drive the disease. Unlike other treatments, such as Wave Life Sciences' WVE-003, an allele-selective antisense oligonucleotide that is now preparing to move into a registrational global trial, AMT-130 doesn't distinguish between healthy and mutant forms of the protein. Instead, it aims to reduce both. It's not yet clear if reducing levels of the healthy protein will have downstream effects. The recent uniQure trial met its primary endpoint by reducing disease progression on a standard composite scale by 75% over 30 months. Progression was compared against an external control group of similar patients from a Huntington's disease registry. "I believe these groundbreaking data are the most convincing in the field to date and underscore potential disease-modifying effects in Huntington's disease, where an urgent need persists," said Dr. Sarah Tabrizi, professor of clinical neurology, director of the University College London Huntington's Disease Centre and joint head of the department of neurodegenerative disease, in a written release. UniQure's drug is one of several Huntington's contenders that target the huntingtin protein, although their methods vary. PTC Therapeutics is developing a small-molecule drug, PTC-518, now in phase 2. It also saw some recent success, hitting its primary endpoint of reducing levels of huntingtin protein in the blood in a 12-week trial. Roche and Ionis Pharmaceuticals are continuing development for their huntingtin-lowering drug tominersen, while looking to find its niche after a phase 3 failure in 2021. The drug originally appeared to worsen symptoms with the most frequent doses, however, later analysis showed a potential benefit in a subset of younger, earlier-stage patients. A targeted trial with that group is ongoing. Where the gene therapy goes from here. Going forward, uniQure will need to prove AMT-130 can deliver results more broadly than the small group of 29 patients in its recent trial. Questions also remain about whether the disease modifying effects will be durable over time or if new safety issues might arise. Dr. Walid Abi-Saab, the chief medical officer of uniQure, said in a press release that company officials believe the drug has the potential to transform treatment for people with Huntington's, and uniQure is aiming to apply for FDA approval in the first quarter of 2026, which could lead to a launch later in the year. But scaling the drug to reach more patients will be a challenge, and like many one-time gene therapies, AMT-130 is expected to come at a high price, potentially raising affordability issues. But this is not uniQure's first gene therapy. The company gained approval in 2022 of the world's first gene therapy for hemophilia B, Hemgenix, which was commercialized by CSL Behring.

PR Newswire
Sep 2nd, 2025
RareMed Announces Expansion of Relationship with PTC Therapeutics

PITTSBURGH, Sept. 2, 2025 /PRNewswire/ - RareMed Solutions(R), the nation's leader in patient support services for complex therapies, is proud to announce an expansion of its relationship with PTC Therapeutics(TM) with the launch of non-commercial pharmacy dispensing services for PTC's therapy, Sephience(TM).

INACTIVE